We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Oxford Genome Sciences Expands its Scientific Advisory Board

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Oxford Genome Sciences (UK) Ltd “OGeS” has announced that it has further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr Mike Gresser.

Dr Gresser, who is currently Visiting Scholar at the Molecular Biology Institute at UCLA, has significant pharmaceutical and academic experience which compliments the skills of the other members of the OGeS’ SAB.

Prior to taking up his current position, Dr Gresser worked at Amgen Inc., Thousand Oaks, CA, USA, where he was for six years Vice President Research for Inflammation and for two years he also held the position of Head of Neuroscience Research.

At Amgen, he worked on many molecular targets, introducing numerous small molecules, human antibodies, and other proteins into development.

Before joining Amgen, Dr Gresser worked for 12 years at the Merck Frost Center for Therapeutic Research in Kirkland, Quebec where his final position was Executive Director of Biochemistry and Molecular Biology. While at Merck, Mike and his team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials, including Singulair and Vioxx.

Dr Gresser received his Ph.D. in Biochemistry in 1976 from Brandeis University, where his thesis research was done under the supervision of W.P. Jencks on the mechanism of ester aminolysis.  He did postdoctoral studies at the Molecular Biology Institute at UCLA on the mitochondrial and chloroplast proton translocating adenosine triphosphate (ATP) synthases. He carried out this work under the supervision of Paul D. Boyer, who won the Nobel Prize in Chemistry in 1997 for his part in the elucidation of the enzymatic mechanism underlying the synthesis of ATP.

Dr Mike Gresser commented: “I have been highly impressed with the progress that Oxford Genome Sciences has made in such a short time. I have little doubt that Christian and his team backed by the unique resources of the OGAP database will be able to play a major role in developing the personalised medicines that are clearly required to improve the treatment of major diseases such as cancer and Alzheimer’s disease.”

“I look forward to contributing to OGeS’s exciting future and to working with my colleagues on the company’s high quality SAB,” he continued.